antazoline phosphate

Trade name: Vasocon A

Small moleculeapproved

Approved

Apr 30, 1990

Antazoline is a 1st generation antihistamine with anticholinergic properties used to relieve nasal congestion and in eye drops, usually in combination with naphazoline, to relieve the symptoms of allergic conjunctivitis. To treat allergic conjunctivitis, antazoline can be combined in a solution with tetryzoline. The drug is a Histamine H1 receptor antagonist: selectively binding to but not activating the receptor, thereby blocking the actions of endogenous histamine and subsequently leading to the temporary relief of the negative symptoms brought on by histamine. — Wikipedia

Clinical trial activity

0 trials · 0 clinical orgs · 1 marketing orgs

Phase 1
0
Phase 2
0
Phase 3
0
Phase 4
0

Timeline

1990s

  1. Apr 30, 1990

    Novartis — Earliest FDA Approval

  2. Apr 30, 1990

    Novartis — NDA Secondary Org

  3. Apr 30, 1990

    Novartis — NDA Organization

Indications

Approved for

Mechanism of action

Combination products

Approval history

  • approvedApr 30, 1990

Chemistry & pharmacology

Loading structure…

SMILES

O=P(O)(O)O.c1ccc(CN(CC2=NCCN2)c2ccccc2)cc1
Mol. weight
363.35 g/mol
Lipinski Ro5
Pass
Rule of 3
No
Chirality
Achiral Molecule
Inorganic
No
Polymer
No
Delivery
Topical
Availability
Discontinued

Oral

No

Parenteral

No

Topical

Yes

Sources

Also known as

  • antazoline phosphate
  • antazoline phosphate
  • antazoline phosphate

Organizations

Marketing (2)

OrganizationOrg typeRelationshipDate
NovartisFor profitNDA2Apr 30, 1990
NovartisFor profitNDAApr 30, 1990